Aytu Biopharma (AYTU) Change in Receivables (2015 - 2026)
Aytu Biopharma (AYTU) reported Change in Receivables of -$6.4 million for Q1 2026, down 161.25% year-over-year from $10.5 million in Q1 2025, and down 179.5% quarter-over-quarter from -$2.3 million in Q4 2025.
Aytu Biopharma (AYTU) Change in Receivables (2015 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 12 years of Change in Receivables data on file, last reported at -$6.4 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$6.4 million, down 161.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.3 million (down 272.62% YoY), and the FY2025 annual result was $7.6 million, up 246.68% from the prior year.
- Change in Receivables declined to -$6.4 million in Q1 2026 per AYTU's latest filing, from -$2.3 million in the prior quarter.
- Over five years, Change in Receivables peaked at $10.5 million in Q1 2025 and troughed at -$6.4 million in Q1 2026.
- A 5-year average of $48764.7 and a median of -$478000.0 in 2024 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables tumbled 2775.45% in 2022, then jumped 2025.42% in 2024.
- A 5-year view of Change in Receivables shows it stood at -$2.4 million in 2022, then jumped by 95.04% to -$118000.0 in 2023, then jumped by 2025.42% to $2.3 million in 2024, then sank by 201.32% to -$2.3 million in 2025, then plunged by 179.5% to -$6.4 million in 2026.
- Business Quant data shows AYTU's Change in Receivables at -$6.4 million in Q1 2026, -$2.3 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -78.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 106.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -38.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 81.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 23.22 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 116.25 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.23 Mn |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn | -6.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.43 Mn |
| Mar 31, 2026 | -6.43 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | -4.67 Mn |
| Jun 30, 2025 | -4.67 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 2.27 Mn |
| Dec 31, 2024 | 2.27 Mn |
| Sep 30, 2024 | -478,000.00 |
| Sep 30, 2024 | -478,000.00 |
| Jun 30, 2024 | -5.73 Mn |
| Jun 30, 2024 | -5.73 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Dec 31, 2023 | -118,000.00 |
| Dec 31, 2023 | -118,000.00 |